Hallucinogenic amphetamines;Amfetaminy halucynogenne

Problems of Forensic Sciences

Volumn 52, Issue , 2002, Pages 64-86

  Nasiadka, Katarzyna ^a   Rutkowska, Anita ^a   Brandys, Jerzy ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Designer drug; Ecstasy; Entactogens; Hallucinogens; Neurotoxicity

Indexed keywords

2,4,5 TRIMETHOXYAMPHETAMINE; 2,5 DIMETHOXY 4 METHYLAMPHETAMINE; 2,5 DIMETHOXYAMPHETAMINE; 3,4 METHYLENEDIOXY N,N DIMETHYLAMPHETAMINE; 3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYETHYLAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 BROMO 2,4 DIMETHOXYPHENETHYLAMINE; 4 METHOXYAMPHETAMINE; 4 METHOXYMETHAMPHETAMINE; 4 METHYLTHIOAMPHETAMINE; 5 METHOXY 3,4 METHYLENEDIOXYAMPHETAMINE; AMPHETAMINE DERIVATIVE; DESIGNER DRUG; MESCALINE; N HYDROXY 3,4 METHYLENEDIOXYAMPHETAMINE; N METHYL 1 (3,4 METHYLENEDIOXYPHENYL) 2 BUTANAMINE; PSYCHEDELIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; HALLUCINATION; HAPPINESS; HUMAN; INTIMACY; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; SELF CONCEPT; SEROTONIN RELEASE; WELLBEING;

EID: 0141590395     PISSN: 12307483     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Amendt G., Walder P., Le nuove droghe. Una guida critica, Universale Economica Feltrinelli, Milano 1998.
2. Bodner R. A., Lynch T., Lewis L. [et al.], Serotonin syndrome, Neurology 1995, vol. 45, pp. 219-223.
3. Crisp T., Stafinsky J. J., Boja J. W. [et al.], The antinociceptive effects of 3,4-methylenedioxymethamphetamine (MDMA) in the rat, Pharmacology Biochemistry & Behavior 1989, vol. 34, pp. 497-501.
4. Dafters R. I., Effect of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") in rats, Psychopharmacology 1994, vol. 114, pp. 505-508.
5. de la Torre R., Farre M., Ortuno J. [et al.], Non-linear pharmacokinetics of MDMA ("ecstasy") in humans, British Journal of Clinical Pharmacology 2000, vol. 49, pp. 104-109.
6. Farré M., Hernàndez-Lòpez C., de la Torre R. [et al.], Pharmacokinetics and pharmacological effects of MDMA in humans, INABIS 2000; 6th Internet World Congress of Biomedical Sciences, http://ecstasy.org/info/novartisabs/.
7. Glennon R. A., Yousif M., Patrick G., Stimulus properties of 1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDA) analogs, Pharmacology Biochemistry & Behavior 1988, vol. 29, pp. 443-449.
8. Gossop M., Narkomania. Mity i rzeczywistość, Wydawnictwo Naukowe PWN, Warszawa 1993.
9. Gouzoulis-Mayfrank E., Thelen B., Habermeyer E. [et al.], Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxy-ethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers, Psychopharmacology 1999, vol. 142, pp. 41-50.
10. Habrat B., Baran-Furga H., Chmielewska K., Z UFO w zaświaty, Wiedza i Życie 2001, nr 3, s. 32-33.
11. Hegadoren K. M., Martin-Iverson M. T., Baker G. B., Comparative behavior and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine, Psychopharmacology 1995, vol. 118, pp. 295-304.
12. Hermle L., Spitzer M., Borchardt D. [et al.], Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents, Neuropsychopharmacology 1993, vol. 8, pp. 171-176.
13. Hołownia S., Te schody nie maja̧, końca, W drodze 2000, nr 11.
14. Jansen K. L. R., Adverse psychological effects associated with the use of "ecstasy" (MDMA) and their treatment, http://ecstasy.org/info/.
15. Jansen K. L. R., Ecstasy (MDMA) dependence, Drug and Alcohol Dependence 1999, vol. 53, pp. 121-124.
16. Kostowski W., Pużyński S., Psychofarmakologia doświadczalna i kliniczna, Wydawnictwo Lekarskie PZWL, Warszawa 1986.
17. Liechti M. E., Baumann C., Gamma A. [et al.], Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) are attenuated by the serotonin uptake inhibitor citalopram, Neuropsychopharmacology 2000, vol. 22, pp. 513-521.
18. Liechti M. E., Gamma A., Vollenweider F. X., Gender differences in the subjective effects of MDMA, Psychopharmacology 2001, vol. 154, pp. 161-168.
19. Malizia E., Borgo S., Smeriglio M. [et al.], Aspetti tossicologici, clinici e sociali dell'ecstasy o metilendiossimetamfetamina, CIC Edizioni Internazionali, Roma 1993.
20. Marona-Lewicka D., Rhee G. S., Sprague J. E. [et al.], Reinforcing effects of certain serotonin-releasing amphetamine derivatives, Pharmacology Biochemistry & Behavior 1996, vol. 53, pp. 99-105.
21. McFadyean M., Narkotyki. Wiedzieć wiȩcej, Emblemat, Warszawa 2000.
22. Metody analizy środków uzależniaja̧cych, Instytut Psychiatrii i Neurologii, Warszawa 1997.
23. Morgan M. J., Ecstasy (MDMA): a review of its possible persistent psychological effects, Psychopharmacology 2000, vol. 152, pp. 230-248.
24. Reneman L., Booij J., Schmand B. [et al.], Memory disturbances in ecstasy users are correlated with altered brain serotonin neurotransmission, Psychopharmacology 2000, vol. 148, pp. 322-324.
25. Robson P., Narkotyki, Wydawnictwo Medycyna Praktyczna, Kraków 1997.
26. Rodgers J., Cognitive performance amongst recreational users of ecstasy, Psychopharmacology 2000, vol. 151, pp. 19-24.
27. Saunders N., Doblin R., Ecstasy. Dance, trance and transformation, Quick American Archives, Oakland 1996.
28. Saunders N., E come ecstasy, Universale Economica Feltrinelli, Milano 1995.
29. Series H., Boeles S., Dorkins E. [et al.], Psychiatric complications of ecstasy use, Journal of Psychopharmacology 1994, vol. 8, pp. 60-61.
30. Shulgin A., Shulgin A., PIHKAL: A chemical love story, Transform Press, Berkeley 1991.
31. Vollenweider F. X., Gamma A., Liechti M. [et al.], Psychological and cardiovascular effects and short-term sequelae of MDMA (Ecstasy) in MDMA - nadve healthy volunteers, Neuropsychopharmacology 1998, vol. 19, pp. 241-251.